1993
DOI: 10.1055/s-2008-1032653
|View full text |Cite
|
Sign up to set email alerts
|

Ganzkörper-Positronen-Emissions-Tomographie beim Mammakarzinom

Abstract: The value of whole body positron emission tomography using F-18 2-deoxy-2-fluoro-d-glucose in primary work-up and follow-up was prospectively evaluated in 37 patients with primary or metastatic breast cancer. From 20 primary breast masses 15 from 16 malignant and 4 from 4 benign lesions confirmed by biopsy, were detected. In 3 out of 21 patients in correlation to morphologic imaging, respectively biopsy, no metastatic disease was not identified. Generally speaking, whole body positron emission tomography appea… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

1996
1996
2011
2011

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 15 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Scintigraphy with radiolabelled monoclonal antibodies has been used for the detection of primary, recurrent and metastatic breast cancer (Rainsbury 1984, Williams et al 1984, Ryan et al 1988, Major et al 1989, Lamki et al 1991, Lind et al 1991. Whole-body positron emission tomography (PET) shows that the uptake of radiolabelled oestrogen analogue (Mintun et al 1988) and radiolabelled glucose analogue (Wahl et al 1991, Nitzsche et al 1993 may occur at primary breast cancer sites and occasionally at sites of lymph node metastasis. The authors state that whole-body PET appears to be a suitable diagnostic staging tool for breast cancer.…”
Section: Imaging With Radionuclidesmentioning
confidence: 99%
“…Scintigraphy with radiolabelled monoclonal antibodies has been used for the detection of primary, recurrent and metastatic breast cancer (Rainsbury 1984, Williams et al 1984, Ryan et al 1988, Major et al 1989, Lamki et al 1991, Lind et al 1991. Whole-body positron emission tomography (PET) shows that the uptake of radiolabelled oestrogen analogue (Mintun et al 1988) and radiolabelled glucose analogue (Wahl et al 1991, Nitzsche et al 1993 may occur at primary breast cancer sites and occasionally at sites of lymph node metastasis. The authors state that whole-body PET appears to be a suitable diagnostic staging tool for breast cancer.…”
Section: Imaging With Radionuclidesmentioning
confidence: 99%